title: Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH).
abstract: BACKGROUND
  The impact of drug-eluting stent (DES) implantation on the incidence of major adverse cardiovascular events in patients undergoing percutaneous intervention for left main (LM) coronary disease is largely unknown.
  
  
  RESULTS
  From April 2001 to December 2003, 181 patients underwent percutaneous coronary intervention for LM stenosis at our institution. The first cohort consisted of 86 patients (19 protected LM) treated with bare metal stents (pre-DES group); the second cohort comprised 95 patients (15 protected LM) treated exclusively with DES. The 2 cohorts were well balanced for all baseline characteristics. At a median follow-up of 503 days (range, 331 to 873 days), the cumulative incidence of major adverse cardiovascular events was lower in the DES cohort than in patients in the pre-DES group (24% versus 45%, respectively; hazard ratio [HR], 0.52 [95% CI, 0.31 to 0.88]; P=0.01). Total mortality did not differ between cohorts; however, there were significantly lower rates of both myocardial infarction (4% versus 12%, respectively; HR, 0.22 [95% CI, 0.07 to 0.65]; P=0.006) and target vessel revascularization (6% versus 23%, respectively; HR, 0.26 [95% CI, 0.10 to 0.65]; P=0.004) in the DES group. On multivariate analysis, use of DES, Parsonnet classification, troponin elevation at entry, distal LM location, and reference vessel diameter were independent predictors of major adverse cardiovascular events.
  
  
  CONCLUSIONS
  When percutaneous coronary intervention is undertaken at LM lesions, routine DES implantation, which reduces the cumulative incidence of myocardial infarction and the need for target vessel revascularization compared with bare metal stents, should currently be the preferred strategy.
authors.affiliation: Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: Marco
authors.initials: M
authors.lastname: Valgimigli
authors.forename: Carlos A G
authors.initials: CA
authors.lastname: van Mieghem
authors.forename: Andrew T L
authors.initials: AT
authors.lastname: Ong
authors.forename: Jiro
authors.initials: J
authors.lastname: Aoki
authors.forename: Gaston A Rodriguez
authors.initials: GA
authors.lastname: Granillo
authors.forename: Eugene P
authors.initials: EP
authors.lastname: McFadden
authors.forename: Arie Pieter
authors.initials: AP
authors.lastname: Kappetein
authors.forename: Pim J
authors.initials: PJ
authors.lastname: de Feyter
authors.forename: Pieter C
authors.initials: PC
authors.lastname: Smits
authors.forename: Evelyn
authors.initials: E
authors.lastname: Regar
authors.forename: Willem J
authors.initials: WJ
authors.lastname: Van der Giessen
authors.forename: George
authors.initials: G
authors.lastname: Sianos
authors.forename: Peter
authors.initials: P
authors.lastname: de Jaegere
authors.forename: Ron T
authors.initials: RT
authors.lastname: Van Domburg
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015331:Cohort Studies; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000628:therapy*; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control*; D004343:Drug Implants; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control; D012042:Registries; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage / Q000627:therapeutic use*; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004343:Drug Implants; D020123:Sirolimus